Vanguard Asset Management
ABUS icon

Vanguard Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Vanguard Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Hold
89,582
– – ﹤0.01% 2243
2026
Q1 		$403K Buy
+89,582
New +$392K ﹤0.01% 2191

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.19B AUM 63.92% 1-Year Est. Return

Vanguard Asset Management's ABUS Position: Q2 2026 in Review

Vanguard Asset Management held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 89,582 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Vanguard Asset Management first reported a position in ABUS in Q1 2026 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Vanguard Asset Management held 89,582 shares of Arbutus Biopharma worth $430K as of Q2 2026.
  • Vanguard Asset Management left its Arbutus Biopharma share count unchanged in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2243 holding.
  • Vanguard Asset Management first reported a position in Arbutus Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.